Introduction
Malignant disease is a major cause of mortality all over the world. The era of chemotherapy commenced in the late 1940s and 1950s with the clinical introduction of the classical alkylating agents such as cyclophosphamide, nitrogen mustard, and melphalan. The discovery of the antitumor effects of cisplatin (cis-diamminedichloroplatinum(II)) in 1965&&Year OK? (cited ref. is from 1969)&& by Rosenberg et al [1] represents a milestone in cancer treatment. Although cisplatin is routinely used nowadays in the treatment of many tumor diseases such as testicular and ovarian cancer, toxic side effects such as nephrotoxicity and myelosuppression [2] were not tolerable and inspired an intensive search for more-tolerable platinum-based drugs. The second-generation platinum drug carboplatin (cisdiamminecyclobutane-1,1'-dicarboxylatoplatinum(II)) went into clinical use in the early 1980s. It possessed decreased side effects and increased water solubility. However, the higher doses needed for cisplatin-like antitumor activity diminished the advantages obtained by the use of the cyclobutane dicarboxylate &&OK?&& leaving group. Randomized trials of cisplatin versus carboplatin in ovarian cancer demonstrated similar responses and recurrence of tumor growth. [3, 4] To overcome this cross-resistance, the so-called third generation of platinum complexes was synthesized. The most promising candidate is oxaliplatin, bearing a 1,2-diaminocyclohexane (DACH) ligand and oxalate as leaving group. [5, 6] Today it is used for the treatment of colorectal cancer, for which both cisplatin and carboplatin have been shown to be clinically inactive.
The mode of action of oxaliplatin differs from that of other platinum complexes. It forms fewer DNA adducts than cisplatin, but the DACH carrier ligand may induce DNA lesions which are poorly recognized by DNA repair pathways. This effect depends on the configuration of the ethylenediamine chelate.
The R,R isomer is more effective than the S,S and R,S/ S,R isomers.
This finding induced us to study stereoisomeric antiproliferative effects in the class of [1,2-diamino-1,2-bis(4-fluorophenyl)ethane]dichloroplatinum(II) (4F-Ph-PtCl 2, ) complexes. [7, 8] However, the attempt failed to increase the antiproliferative effects by separation into enantiomerically pure compounds. [9] In an earlier study, we demonstrated the increase of in vitro cytotoxicity by the exchange of one 4-fluorophenyl residue with a methyl (4F-Ph/Me-PtCl 2 ), ethyl (4F-Ph/Et-PtCl 2 ) or propyl group (4F-Ph/ Prop-PtCl 2 ). [10] [11] [12] Interestingly, the C2-methyl substituent led to different cytotoxic effects of the threo isomers: S,S > R,R > S,R = R,S. [10] Elongation of the side chain in the erythro series with one or two methylene groups also produced this effect: &ok? &R,R > S,S > R,S > S,R. [11, 12] Our aim now is to optimize cytotoxic potency with the use of branched C2-alkyl chains. Herein, we report the synthesis of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes and their antiproliferative effects on the MCF-7 and MDA-MB 231 breast cancer cell lines as well as on the LNCaP/FGC prostate cancer cell line.
A series of leaving group derivatives of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes were synthesized and tested for cytotoxicity. The enantiomeric purity was determined by 1 H NMR spectroscopy on the final diamines after derivation with (1R)-myrtenal. For coordination to platinum, the diamines were reacted with K 2 PtI 4 . The treatment of diiodoplatinum(II) complexes (4F-Ph/iProp-PtI 2 ) with Ag 2 SO 4 resulted in the sulfatoplatinum(II) complexes (4F-Ph/ iProp-PtSO 4 ), which can be easily transformed into dichloroplatinum(II) complexes (4F-Ph/iProp-PtCl 2 ) with 2 n HCl. The importance of the leaving groups and the configuration at the diamine ligand on the antiproliferative effects was evaluated on the hormone-dependent MCF-7 and the hormone-independent MDA-MB 231 breast cancer cell lines as well as the LNCaP/FGC prostate cancer cell line. (R,R)-4F-Ph/iProp-PtCl 2 was identified as the most active platinum(II) complex. The 3-methyl group increased antiproliferative effects relative to the [1,2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes described in an earlier study.
Results and Discussion

Synthesis
The erythro-configured compounds were obtained using a previously published, modified method reported by O'Brien and Poumellec (Scheme 1). [13] The synthesis of (1S,2R)-1,2-diamino-1-(4-fluorophenyl)-3-methylbutane (1S,2R)-6 started from (2R)-2-amino-3-methylbutanol (2R)-1, which was first N-protected by two benzyl groups and oxidized to the aldehyde (2R)-3. The reaction with 4-fluorophenylmagnesium bromide resulted in a mixture of the diastereomeric amino alcohols (1S,2R)-4 and (1R,2R)-4 in a ratio of 90:10. After separation by column chromatography, the hydroxy group of (1S,2R)-4 was activated through mesylate formation. This unstable intermediate could not be isolated because it cyclized readily to an aziridinium ion. Ring opening with N 3 -yielded mainly (1S,2R)-5 (93 %), which was separated by column chromatography. Reduction and deprotection resulted in the diamine (1S,2R)-6 in an overall yield of 33 %.
For the preparation of the threo-configured diamines, a procedure described by Merino et al. (Scheme 2) was used. [14] (2R)-1 was protected with a tert-butoxycarbonyl group to give (2R)-7, which was oxidized to the aldehyde (2R)-8. This was allowed to react with N-benzylhydroxylamine to form the nitrone (2R)-9. Addition of 4-fluorophenylmagnesium bromide produced (1R,2R)-10 as a diastereomeric mixture with (1S,2R)-10 ( % 78:22). After separation, (1R,2R)-10 was reduced to (1R,2R)-11 and deprotected to obtain (1R,2R)-12 in an overall yield of 10 %.
Using (2S)-2-amino-3-methylbutanol (2S)-1, the diamines (1R,2S)-6 and (1S,2S)-12 were also made available. In each case, the enantiomeric purity was determined by 1 H NMR spectroscopy with (1R)-(À)-myrtenal as chiral derivatizing agent. K 2 PtI 4 , synthesized in situ from K 2 PtCl 4 and KI, was used for the coordination of the 1,2-diaminobutanes 7 and 13 (Scheme 3). The reaction with Ag 2 SO 4 yielded the respective sulfatoplatinum(II) complexes, which were then transformed into the dichloroplatinum(II) complexes by addition of 2 n HCl. (Scheme 3).
Structural characterization
The 1 H NMR spectra of the platinum complexes showed characteristic resonances for the amino and methine protons. The protons of both amino groups were diastereomerically split into four signals due to a stable five membered chelate ring at the platinum. If the coordination to platinum was performed in D 2 O, a quantitative NH/ND exchange took place and allowed a conformational analysis based on the splitting of the benzylic proton due to the 3 J coupling to the neighboring methine proton and 195 Pt. In particular, the platinum satellites resulting J CHÀPt = 81 Hz. This indicated a preference for the conformer with an axially oriented aromatic ring. [15] Antitumor activity (Figure 1 ). LNCaP/FGC cells were somewhat more resistant against cisplatin (maximal T/C corr = 20 % at 5 mm; Figure 1 ).
The effects of the [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes depended on the configuration/ conformation of the ethylenediamine ligand and the kind of leaving groups present. The complexes with SO 4 2À or Cl À as leaving groups showed similar cytotoxicity and were by far more active than their diiodoplatinum(II) derivatives. The threo-configured complexes were more active than the erythroconfigured congeners. The separated enantiomers differed in their antiproliferative activity depending on the cell line used.
The (S,S)-and (R,R)-4F-Ph/iProp-PtI 2 complexes showed similar cytostatic effects on the MCF-7 cell line at a concentration of 5 mm during the whole incubation time of 220 h:T/C corr = 0 % (Figures 2 and 3) . At lower concentrations (R,R)-4F-Ph/iProp-PtI 2 was slightly more active than (S,S)-4F-Ph/iProp-PtI 2 ( Figure 2 ). The comparison of the time-activity curves determined with the sulfatoplatinum(II) complexes indicates no significant differences between the enantiomers regarding their cytotoxicity. The enantiomeric dichloroplatinum(II) complexes showed the most significant differences in cytotoxicity. (R,R)-4F-Ph/ iProp-PtCl 2 was the most active compound in this study and caused cytostatic effects at the low concentration of 0.5 mm. Furthermore, it was more active than (S,S)-4F-Ph/iProp-PtCl 2 at each concentration. It should be noted that with the exception of (S,S)-4F-Ph/iProp-PtI 2 , all threo-configured complexes had similar or greater activity than that of cisplatin.
Among the erythro series ( Figure 3 ) (R,S)-and (S,R)-4F-Ph/ iProp-PtSO 4 , and (S,R)-4F-Ph/iProp-PtCl 2 showed cisplatin-like effects. The dichloroplatinum(II) complexes also possessed significant stereoisomeric differences (cytotoxicity of (S,R)-4F-Ph/ iProp-PtCl 2 > (R,S)-4F-Ph/iProp-PtCl 2 ). Therefore, the tests on the MDA-MB 231 and the LNCaP/FGC cell lines were only performed with these leaving group derivatives.
The growth-activity curves of MDA-MB 231 cells during drug exposure ( Figure 4 ) were characterized by a very fast onset of activity followed by a strong recuperation of the cells. Because exponential cell growth is guaranteed for at least 180 h of incubation, the rise of the growth curve can be explained by the development of drug resistance. [16] A C H T U N G T R E N N U N G (S,S)-4F-Ph/iProp-PtCl 2 and (R,R)-4F-Ph/iProp-PtCl 2 caused identical cytocidal effects after an incubation period of 48 h at all concentrations tested and a similar recovery of cell growth at the lower concentrations. However, at 5 mm,of (R,R)-4F-Ph/ iProp-PtCl 2 was able to terminate cell division completely for the duration of the test. Interestingly, great differences were observed between the erythro-configured compounds. (R,S)-4F-Ph/iProp-PtCl 2 was about fivefold less active than (S,R)-4F-Ph/ iProp-PtCl 2 , which, in turn, was about fivefold less cytotoxic than (R,R)-4F-Ph/iProp-PtCl 2 .
The most promising results were obtained with the LNCaP/ FGC prostate cancer cell line ( Figure 5 ). (S,S)-4F-Ph/iProp-PtCl 2 and (R,R)-4F-Ph/iProp-PtCl 2 inhibited cell growth at a very low concentration (0.05 mm), indicating 100-fold higher cytotoxicity than cisplatin. The stereoselectivity was similar to that observed with breast cancer cells: This study was a continuation of our attempts to optimize the antitumor activity of [S,S/R,R-1,2-diamino-1,2-bis(4-fluorophenyl)ethane]dichloroplatinum(II) ((R,R/S,S)-4F-Ph/4-Ph-PtCl 2 ). (R,R/S,S)-4F-Ph/4-Ph-PtCl 2 showed high activity in vitro and in vivo against a wide range of murine tumors, [7, 8] and was more active than cisplatin and its R,S/S,R-configured diastereomeric congener. The attempt to optimize the antitumor activity of (R,R/S,S)-4F-Ph/4-Ph-PtCl 2 failed because of a separation of enantiomers. The separated (R,R)-and (S,S)-4F-Ph/4-Ph-PtCl 2 possessed identical effects in vitro on the MCF-7 cell line and in vivo on P388 leukemia implanted in mice. [9] This negative result was not predictable because asymmetric DNA was identified as a target of (R,R/S,S)-4F-Ph/4-Ph-PtCl 2 . [17] The mode of&ok?& DNA attack should be identical for the enantiomers, resulting in diastereomeric adducts with the chiral DNA that should form intrastrand cross links with different kinetics. However, this last step in the reaction with the target seems to be identical for the enantiomers. We ascribed this phenomenon to the equal substitution of the asymmetric C atoms. Therefore, we tried to optimize the activity of 4F-Ph/ 4-Ph-PtCl 2 complexes by exchanging one aromatic ring with alkyl chains of various lengths. Structural modification increased the cytotoxicity observed with the human MCF-7 and MDA-MB 231 cell lines (4-fluorophenyl methyl < ethyl % propyl % butyl). The maximal effect was observed with the [1,2-diamino-1-(4-fluorophenyl)butane]-platinum(II) complex ((R,R/S,S)-4F-Ph/Et-PtCl 2 ), the cytotoxicity of which could be optimized by separation of the enantiomers: (R,R)-4F-Ph/Et-PtCl 2 showed a significantly higher activity than (S,S)-4F-Ph/Et-PtCl 2 . The same enantioselectivity was observed for the erythro compounds: (R,S)-4F-Ph/Et-PtCl 2 was more active than (S,R)-4F-Ph/Et-PtCl 2 . [11] The lack of enhancement of the cytotoxicity by elongation of the ethyl chain prompted us to investigate the influence of a branched isopropyl group at C2 on the antiproliferative effects. This structural modification only marginally affected the activity of the threo-configured complexes on the MCF-7 cell line ( Figure 2 ) but was of great significance for their effects on the MDA-MB 231 cell line (Figure 4 ). In contrast with (R,R)-and (S,S)-4F-Ph/Et-PtCl 2 , strong cytocidal effects were observed for the respective C2-isopropyl derivatives, whereby (R,R)-4F-Ph/iProp-PtCl 2 maintained the cytocidal effects at a concentration of 5 mm for the duration of the experiment.
A more pronounced enantioselectivity was observed in the eythro series: (S,R)-4F-Ph/iProp-PtCl 2 was distinctly more active than (R,S)-4F-Ph/iPropPtCl 2 , again to a greater extent on the MDA-MB 231 cell line, on which (S,R)-4F-Ph/iProp-PtCl 2 caused cytocidal effects even at the low concentration of 1 mm &ok?&. In comparison, the C2-ethyl derivative (S,R)-4F-Ph/Et-PtCl 2 was nearly inactive (T/C corr % 70 %) at this concentration.
This enhanced activity and stronger enantioselectivity observed with the erythro series might be the consequence of the dynamic behavior of the fivemembered chelate ring induced by the 3-methyl group at the 1,2-diaminobutane moiety. For (S,R)-4F-Ph/Et-PtCl 2 , an interconversion of the chelate ring was verified with a preference for the conformation with the axially oriented aromatic ring. The platinum satellites of J CHÀPt = 60 Hz indicated a portion of about 75 % at room temperature. In the case of (S,R)-4F-Ph/ iProp-PtCl 2 , the coupling-constant analyses demonstrated that the isopropyl group forced the aromatic ring in an axial position in a nearly quantitative manner.
It should be mentioned that in the threo series only one stable conformation was observed with the alkyl chain and the aromatic ring in an equatorial position. We assume that the conformational behavior of the five-membered ring is highly relevant for DNA binding. The threo-configured complexes could easily be bound to the nucleobases because of their relatively flat conformation. The ethyl group in (S,R)-4F-Ph/Et-PtCl 2 , and to a much greater extent, the isopropyl group in (S,R)-4F-Ph/iProp-PtCl 2 force the aromatic ring into an axial position. On the one hand, this might hinder DNA binding, but on the other, it is very likely that the DNA lesion is more pronounced after bifunctional binding owing to the predominant axial position of the aromatic ring.
It is well known that increased bulk can alter the interactions of proteins and enzymes with DNA adducts and can influence the nature and lifetime of conformations at the Pt-dA C H T U N G T R E N N U N G (GpG) binding site. In this way, the carrier ligand could affect the anticancer activity, the tumor selectivity, and the cross-resistance to cisplatin. [18] These are not the final page numbers! ÞÞ
Synthesis and Cytotoxicity of Platinum(II) Complexes
To determine if [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes are able to overcome cisplatin resistance, we used the LNCaP/FGC prostate cancer cell line as a model. Cisplatin showed only low antiproliferative effects with a T/C corr % 20 % at the highest concentration used (5 mm). The time-activity curves in Figure 5 clearly demonstrate that these prostate cancer cells showed an increased sensitivity to our novel platinum complexes. To achieve cisplatin-like effects, only 0.05 mm (S,S)-and (R,R)-4F-Ph/iProp-PtCl 2 were necessary.
The greater potency of the [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes in LNCaP/FGC cells, could be the result of increased cellular uptake, increased DNA adduct levels, or decreased DNA damage tolerance &ok?& in comparison with cisplatin. Currently, the determination of these pharmacological parameters is under investigation, and the results will be presented in a forthcoming paper.&citation?& 19 mol) in dry CH 2 Cl 2 (25 mL) was added. After 2 min of stirring, a solution of (2R)-N,N-dibenzyl-2-amino-3-methylbutanol ((2R)-2) (27 g, 95 mmol) in dry CH 2 Cl 2 (50 mL) was added dropwise over 5 min. This mixture was stirred for 15 min, and TEA (48 g, 0.475 mol) was added. The suspension formed was stirred at~À30 8C for 5 min and then allowed to warm to room temperature. Water (200 mL) was added, and the mixture was decanted. The organic layer was washed with brine (50 mL), dried over MgSO 4 , filtered, and evaporated under reduced pressure. The crude product (brown oil; yield: 23.5 g; 88 %) was not purified before analysis and was used directly for the next step. 
Experimental Section
1 H and 13 C NMR spectra were taken at 293 K on a Bruker Avance 300 MHz spectrometer with TMS as internal standard. IR analysis was performed with a Shimadzu IR-470 spectrophotometer. Melting points (uncorrected) were measured with a Mettler FP1 apparatus. All CC purifications were done using silica gel Kieselgel 100 (Merck). TLC was performed on Kieselgel 60 F 254 plates (Merck). Mass spectra were recorded on a Thermo-Fisons VG Auto Spec (70 eV). Specific rotations were measured with a Perkin-Elmer 141 polarimeter. Experimental procedures were performed with either (
A C H T U N G T R E N N U N G (1S,2R)-N,N-dibenzyl-2-amino-1-(4-fluorophenyl)-3-methylbutanol ((1S,2R)-4):
A 1m solution of 4-fluorophenylmagnesium bromide in THF (78 mL, 78 mmol) was added dropwise to a solution of (2R)-N,N-dibenzyl-2-amino-3-methylbutanal ((2S)-3) (20 g, 71 mmol) at 0 8C. The solution was stirred for 2 h at 0 8C and then poured into a saturated NH 4 Cl solution (100 mL). The mixture was extracted twice with diethyl ether (100 mL). The organic layers were collected, washed with brine (50 mL), dried over MgSO 4 , filtered, and evaporated under reduced pressure (viscous yellow oil, 26.7 g). The diastereomeric mixture (90:10) was separated by column chromatography (petroleum ether 40-60 /acetone 95:5). Yield: 18.8 g (70 %) of a light yellow viscous oil. 
A C H T U N G T R E N N U N G (1S,2R)-N,N-dibenzyl-2-amino-1-azido-1-(4-fluorophenyl)-3-methylbutane ((1S,2R)-5): (1S,2R)-N,N-dibenzyl-2-amino-1-(4-fluorophenyl)-3-methylbutanol ((1S
,
d Ar). A C H T U N G T R E N N U N G (1S,2R)-1,2-diamino-1-(4-fluorophenyl)-3-methylbutane ((1S,2R)-6):
Palladium on charcoal 10 % (0.9 g) was added to a solution of (1S,2R)-N,N-dibenzyl-2-amino-1-azido-1-(4-fluorophenyl)-3-methylbutane ((1S,2R)-5) (9 g, 22 mmol) in MeOH (75 mL). This suspension was stirred at reflux for 30 min. Then, ammonium formate (2.8 g, 44 mmol) was added, and the mixture was stirred for 10 h. An equal amount of ammonium formate was added, and the reaction was continued for 10 h. The reaction medium was filtered on celite, and the solvent evaporated under reduced pressure. The oily residue was dissolved in CH 2 Cl 2 (100 mL). This solution was washed with a solution of sodium carbonate 20 % (w/v) (50 mL) and brine (50 mL). It was further dried over These are not the final page numbers! ÞÞ into a three-necked flask under N 2 and cooled to À60 8C. This temperature was maintained during the reaction. Anhydrous DMSO (13.9 g, 0.178 mol) in dry CH 2 Cl 2 (50 mL) was added dropwise. After 2 min of stirring, a solution of (2R)-N-(tert-butoxycarbonyl)-2-amino-3-methylbutanol ((2R)-7) (18 g, 89 mmol) in dry CH 2 Cl 2 (50 mL) was added dropwise. After 5 min of stirring, TEA (45 g, 0.445 mol) was added. The suspension was stirred at~À30 8C for an additional 5 min, and then it was allowed to warm to room temperature. Water (200 mL) was added. After decantation, the organic layer was washed with brine (50 mL), dried over MgSO 4 , filtered, and evaporated under reduced pressure. The yellow oil (yield: 15.1 g, 85 %) was not purified before analysis and was used directly for the next step. 2 -(tert-butoxycarbonyl)-2-amino-1-(4-fluorophenyl)-1-hydroxyamino-3-methylbutane ((1R,2R)-10) (9 g, 22 mmol) was dissolved in MeOH (250 mL), and palladium on charcoal 10 % (0.9 g) was added. The suspension was held at reflux for 30 min. Ammonium formate (2.8 g, 45 mmol) was added, and the suspension was kept at reflux for 12 h. Then, an equal amount of ammonium formate was added, and the reaction was continued for 12 h. The cooled reaction mixture was filtered on celite, and the solvent was evaporated under reduced pressure. The residue was extracted with CH 2 Cl 2 (100 mL). This solution was washed with brine (50 mL), dried over MgSO 4 , filtered, and evaporated under reduced pressure. The oily residue (6.5 g) was used directly for the next step.
The product of the previous step was brought into a solution of HCl in anhydrous MeOH (10 % (w/v)) (50 mL). This solution was stirred at room temperature for 8 h. Then the solvent was evaporated under reduced pressure. The yellow solid obtained was treated with water (50 mL), NaOH 40 % (w/v) (10 mL), and extracted twice with CH 2 Cl 2 (100 mL). The organic solution was washed with brine (50 mL), dried over MgSO 4 , filtered, and evaporated under reduced pressure. The liquid obtained was dissolved in MeOH (20 mL), and a solution of d-(À)-(2S,3S)-tartaric acid (3.3 g, 22 mmol) in MeOH (20 mL) was added. This mixture was heated at reflux for 10 min and then it was allowed to cool to room temperature. The white crystals (1.52 g) were collected by filtration, washed twice with MeOH, and dried at 60 8C under 13.3 kPa (yield: 20 %). Small fractions of this salt were transformed into base and hydrochloride for analysis; mp: 277.5 8C with some decomposition. Enantiomeric excess for the two enantiomers: 98 % ee. ), and 7.5 % FCS) were maintained under the same conditions. The cell lines were passaged weekly after treatment with trypsin (0.05 %)/ethylenediaminetetraacetic acid (EDTA, 0.02 %, Boehringer). Mycoplasma contamination was regularly monitored and only mycoplasma-free cultures were used. In vitro chemosensitivity assays: The in vitro testing of the platinum complexes for antitumor activity was carried out on exponentially dividing human cancer cells according to a previously published microtiter assay. [16, 20] Briefly, 100 mL of a cell suspension of 7700 cells mL À1 culture medium (MCF-7) resp. at 3200 cells mL
À1
(MDA-MB 231) resp. at 2700 cells mL À1 (LNCaP/FGC) were plated into each well of a 96-well microtiter plate and incubated at 37 8C for 3 days resp. 5 days (LNCaP/FGC) in a humidified atmosphere (5 % CO 2 ). By adding an adequate volume of a stock solution of the appropriate compound (solvent: DMF) to the medium, the desired test concentration was obtained. 16 wells were used for the control (containing the appropriate amount of DMF) and each test concentration. After the proper incubation time the medium was removed, and the cells were fixed with a glutardialdehyde solution and stored under phosphate buffered saline (PBS) at 4 8C. Cell biomass was determined by a crystal violet staining technique described previously. [16, 20] The efficiency of the complexes is expressed as corrected % T/C corr values according to the following equations: in which T (test) and C (control) are the optical density values at 578 nm of the crystal violet extract of the cells in the wells (that is, the chromatin-bound crystal violet extracted with 70 % ethanol), and C o is the density of the cell extract immediately before treatment.
A microplate reader at 590 nm (Flashscan AnalytikJena AG) was used for the automatic estimation of the optical density of the crystal violet extract in the wells. The calculated % T/C values can be interpreted as followed: T/C > 80 %: no antiproliferative effect; 80 % > T/C > 20 %: antiproliferative effect; 20 % > T/C > 0 % : cytostatic effect; T/C < 0 % : cytocidal effect
